Intrinsic Medicine, Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Despite being one of the four compounds common to all life, bioactive sugars (glycans) have not been broadly translated as a therapeutic modality. Intrinsic Medicine is an AI enabled platform company with two clinical stage assets that has uncovered the ultimate library of glycans. Our drug candidates encompass the best attributes of direct-acting small molecules and microbiome therapeutics, without the limitations of either. All are supported by positive preclinical data in multiple models of disease along with exceptionally clean toxicology.

Our lead program has the potential to become the first IBS drug capable of serving all patients with comparable disease-modifying efficacy across subtypes and is supported by substantial (n=317) open-label clinical efficacy data. Our second clinical stage candidate has potential to treat Juvenile Idiopathic Arthritis, Atopic Dermatitis, and Autism Spectrum Disorder (all based on existing positive in vivo preclinical data).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Washington
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
OM002
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
Intrinsic Medicine